Help

Bloomberg

Company In Depth Fundamentals - Profile

Ticker: vtrs US EQUITY

Viatris Inc (NASDAQ GS: VTRS, Currency: USD)

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Website	www.viatris.com/en
Number of Employees	45,000
Ticker:	VTRS US

1000 Mylan Blvd Canonsburg, PA 15317 United States
Phone : 1-724-514-1800
Fax : --

15.26 +0.13 (0.83%)

FECHA: 31/12/2021

Stock Quote & Chart (Currency: USD)

Last (delayed quote)	15.25	Market Cap (MM)	18,437.2
Open	15.26	Shares Out. (MM)	1,209.4
Previous Close	15.13	Float %	99.7%
Change	0.00	Shares sold short (MM)	19,986,851.0
Change %	0.00	Dividend Yield %	2.2
Day High/Day Low	15.3 / 15.2	Diluted EPS Excl. XO	0.6
52 Wk High/52 Wk low	18.7 / 12.0	P / Diluted EPS Before XO	--
Volume (MM)	1.17	Beta	0.84
Avg. Vol - 3 mo (MM)	10.48		



Financial Information (Currency: USD, in mm)

Revenue - LTM	17,168.2	Cash & ST Invst.	884
EBIT - LTM	-837.5	Total Assets	61,553.0
EBITDA - LTM	3,872.3	Total Debt	26,161.0
Net Income - LTM	-1,921.1	Total Liabilities	38,598.9
Total Enterprise Value	41,369	Total Equity	22,954.1
TEV/ Total Revenue	2.3 x	Cash from Operations - LTM	2,530.0
TEV/ EBITDA	10.2 x	Cash From Investing - LTM	79.0
		Cash from Financing -LTM	-2,514.5

Company Notes

2014 A1
GAAP Net Income includes. (in millions.pre-tax):
a loss of $2.427 from Debt Extinguishment/Settlement
a loss of $26.725 from Restructuring
an after-tax loss of $20.048 from Tax Adjustment
an after-tax loss of $122.98 from Discontinued operations

2014 Q4
GAAP Net Income includes, (in millions, pre-tax):
a loss of $2.427 from Debt Extinguishment/Settlement
a loss of $13.861 from Restructuring
a gain of $9.086 from Discontinued Operations

2014 Q3
GAAP Net Income includes, (in millions):
a pre-tax loss of $8.290 from Restructuring
an after-tax provision of $20.048 from Tax Adjustment
an after-tax gain of $29.758 from Discontinued Operations

2014 Q2
GAAP Net Income includes, (in millions):
a pre-tax loss of $4.574 from Restructuring
a after tax loss of $181.729 from Discontinued Operations

2014 Q1
GAAP Net Income includes, (in millions, pre-tax):
an after-tax gain of $19.905 from Discontinued Operations

2013 A1

Key Board Members

Name	Title	Organization
W Don Cornwell	Co-Founder	Granite Broadcasting Corp
	Board Member	Viatris Inc
	Board Member	Natura & Co Holding Sa
	Board Member	American Intl Group Inc
	Trustee	Edna Mcconnell Clark Foundatio
Neil F Dimick	Board Member	Viatris Inc
	Board Member	Resources Connection Inc
James Marshall Kilts "Jim"	Founding Partner	Centerview Partners
	Founding Partner/Co-Founder	Centerview Capital Holdings Ll
	Co-Ceo	Conyers Park Iii Acquisition C
	Board Member	Viatris Inc
	Chairman	Advantage Solutions Inc
	Chairman	Simply Good Foods Co/The
	Board Member	Unifi Inc
	Trustee	University Of Chicago
	Board Member	Cato Inst
Ian C Read	Operating Executive:Global Healt	Carlyle Group Inc/The
	Chairman/Co-Founder	Population Health Investment C
	Chairman	Trinetx Inc
	Board Member	Viatris Inc
	Board Member	Avateramedical Nv
	Board Member	Kimberly-Clark Corp
	Chairman	Dxc Technology Co
	Board Member	Pharmaceutical Research And Ma
Harry A Korman "Hal"	Board Member	Viatris Inc
Joellen Lyons Dillon	Board Member	Viatris Inc
Melina E Higgins	Chairman	Antares Capital Corp
	Chairman	Antares Capital Lp
	Chairman	Genworth Financial Inc

Bloomberg

Company In Depth Fundamentals - Key Stats

Ticker: vtrs US EQUITY

Period Type: Annuals

Viatris Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Annuals

FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	0FY	-0FQ	1FY	2FY	3FY

Key Financials

	Actuals							LTM	Estimates		
For the Fiscal Period Ending	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	30/09/2021	30/09/2021	31/12/2021	31/12/2022	31/12/2023
Currency	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*
Total Revenue	**7,719.6**	**9,429.3**	**11,076.9**	**11,907.7**	**11,433.9**	**11,500.5**	**11,946.0**	**17,168.2**	**4,339.9**	**4,339.9**	**4,339.9**
Growth Over Prior Year	*11.7%*	*22.1%*	*17.5%*	*7.5%*	*(4.0%)*	*0.6%*	*3.9%*	*49.1%*	*19.8%*	*19.8%*	*19.8%*
										03/07/2021	
Gross Profit	**3,528.0**	**4,216.1**	**4,697.0**	**4,783.1**	**4,001.6**	**3,897.6**	**3,796.7**	**4,735.5**	--	--	--
Margin %	*45.7%*	*44.7%*	*42.4%*	*40.2%*	*35.0%*	*33.9%*	*31.8%*	*27.6%*	--	--	--
EBITDA	**1,919.2**	**2,493.0**	**2,224.6**	**3,242.9**	**3,015.5**	**2,822.4**	**2,086.0**	**3,872.3**	**1,491.3**	**1,491.3**	**1,491.3**
Margin %	*24.9%*	*26.4%*	*20.1%*	*27.2%*	*26.4%*	*24.5%*	*17.5%*	*22.6%*	*34.4%*	*34.4%*	*34.4%*
EBIT	**1,352.6**	**1,460.9**	**701.6**	**1,437.1**	**905.6**	**715.5**	**(210.8)**	**(837.5)**	**1,381.9**	**1,381.9**	**1,381.9**
Margin %	*17.5%*	*15.5%*	*6.3%*	*12.1%*	*7.9%*	*6.2%*	*(1.8%)*	*(4.9%)*	*31.8%*	*31.8%*	*31.8%*
Earnings from Cont. Ops.	**933.1**	**847.7**	**480.0**	**696.0**	**352.5**	**16.8**	**(669.9)**	**(1,921.1)**	--	--	--
Margin %	*12.1%*	*9.0%*	*4.3%*	*5.8%*	*3.1%*	*0.1%*	*(5.6%)*	*(11.2%)*	--	--	--
Net Income	**929.4**	**847.6**	**480.0**	**696.0**	**352.5**	**16.8**	**(669.9)**	**(1,921.1)**	**1,012.9**	**1,012.9**	**1,012.9**
Margin %	*12.0%*	*9.0%*	*4.3%*	*5.8%*	*3.1%*	*0.1%*	*(5.6%)*	*(11.2%)*	*23.3%*	*23.3%*	*23.3%*
Diluted EPS Excl. Extra Items	**2.3**	**1.7**	**0.9**	**1.3**	**0.7**	**0.0**	**(1.1)**	**(1.9)**	**0.8**	**0.8**	**0.8**
Growth Over Prior Year	*48.1%*	*(27.4%)*	*(45.9%)*	*41.3%*	*(47.7%)*	*(95.6%)*	--	*(465.7%)*	*8.5%*	*8.5%*	*8.5%*

Current Capitalization (Millions)

Currency	USD
Share Price (USD)	15.25
Shares Out.	1,209.39
Market Capitalization (USD)	**18,439.62**
- Cash & Short Term Investments	795.30
+ Total Debt	23,724.80
+ Pref. Equity	0.00
+ Total Minority Interest	0.00
= Total Enterprise Value (USD)	**41,369.12**
Book Value of Common Equity	21,141.30
+ Pref. Equity	0.00
+ Total Minority Interest	0.00
+ Total Debt	23,724.80
= Total Capital	**44,866.10**



Valuation Multiples based on Current Capitalization

	Actual	LTM	Estimates		
For the Fiscal Period Ending	30/09/2021	30/09/2021	30/09/2021	30/09/2021	30/09/2021
TEV/Total Revenue	4.0x	2.3x	9.0x	9.0x	9.0x
TEV/EBITDA	23.0x	10.2x	6.1x	6.1x	6.1x
TEV/EBIT	--	--	6.8x	6.8x	6.8x
P/Diluted EPS Before Extra	--	--			
P/BV	1.0x	0.8x	0.4x	0.4x	0.4x
Price/Tang BV	--	--			

Valuation Multiples for Chart

For the Fiscal Period Ending	TTM	FY1	NTM	FY2
PE Ratio	24.6x	4.1x	4.1x	4.1x
TEV / EBITDA	10.2x	6.1x	6.1x	6.1x
Price / CF	7.2x	4.1x	4.1x	4.1x
Price / Book	0.9x	0.4x	0.4x	0.4x
Dividend Yield	2.2x	3.8x	3.8x	3.8x

PE Ratio



Ticker:	vtrs US EQUITY	vtrs US EQUITY	Ascend	Currency	Reporting	Change	USD
Period Type	Annuals	Consolidated	Yes	Accounting	Mixed		

Viatris Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Income Statement

Income Sheet as of:	31/12/2010	31/12/2011	31/12/2012	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020
Currency	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*
Revenue	5,404.27	6,106.28	6,750.20	6,856.60	7,646.50	9,362.60	10,967.10	11,760.00	11,268.70	11,370.30	11,819.90
Other Revenue	46.26	23.55	45.90	52.50	73.10	66.70	109.80	147.70	165.20	130.20	126.10
Total Revenue	**5,450.52**	**6,129.83**	**6,796.10**	**6,909.10**	**7,719.60**	**9,429.30**	**11,076.90**	**11,907.70**	**11,433.90**	**11,500.50**	**11,946.00**
Cost Of Goods Sold	3,233.13	3,566.46	3,887.80	3,868.80	4,191.60	5,213.20	6,379.90	7,124.60	7,432.30	7,602.90	8,149.30
Gross Profit	**2,217.40**	**2,563.36**	**2,908.30**	**3,040.30**	**3,528.00**	**4,216.10**	**4,697.00**	**4,783.10**	**4,001.60**	**3,897.60**	**3,796.70**
Selling General & Admin Exp.	1,213.67	1,263.19	1,397.60	1,397.00	1,593.60	2,083.30	3,168.60	2,562.70	2,391.50	2,542.20	3,452.40
R & D Exp.	282.15	294.73	401.30	507.80	581.80	671.90	826.80	783.30	704.50	639.90	555.10
Depreciation & Amort.	-	-	-	-	-	-	-	-	-	-	-
Other Operating Expense/(Income)	-	-	-	-	-	-	-	-	-	-	-
Operating Expense., Total	**1,495.81**	**1,557.92**	**1,798.90**	**1,904.80**	**2,175.40**	**2,755.20**	**3,995.40**	**3,346.00**	**3,096.00**	**3,182.10**	**4,007.50**
Operating Income	**721.58**	**1,005.45**	**1,109.40**	**1,135.50**	**1,352.60**	**1,460.90**	**701.60**	**1,437.10**	**905.60**	**715.50**	**(210.80)**
Interest Expense	331.46	335.94	308.70	313.30	333.20	339.40	454.80	534.60	542.30	517.30	497.80
Interest Income	-	-	-	-	-	-	-	-	-	-	-
Net Interest Exp.	**331.46**	**335.94**	**308.70**	**313.30**	**333.20**	**339.40**	**454.80**	**534.60**	**542.30**	**517.30**	**497.80**
Currency Exchange Gains (Loss)	-	-	-	-	-	-	-	-	-	-	-
Other Non-Operating Inc. (Exp.)	34.18	14.87	(3.50)	74.90	44.90	206.10	125.10	(0.50)	64.90	43.80	12.60
EBT Excl. Unusual Items	**355.94**	**654.64**	**804.20**	**747.30**	**974.50**	**915.40**	**121.70**	**903.00**	**298.40**	**154.40**	**(721.20)**
Impairment of Goodwill	-	-	-	-	-	-	-	-	-	-	-
Gain (Loss) On Sale Of Assets	-	-	-	-	-	-	-	-	-	-	-
Asset Writedown	-	-	-	-	-	-	-	-	-	-	-
Legal Settlements	-	-	-	-	-	-	-	-	-	-	-
Other Unusual Items	-	-	-	-	-	-	-	-	-	-	-
EBT Incl. Unusual Items	**355.94**	**654.64**	**804.20**	**747.30**	**974.50**	**915.40**	**121.70**	**903.00**	**298.40**	**154.40**	**(721.20)**
Income Tax Expense	10.40	115.83	161.20	120.80	41.40	67.70	(358.30)	207.00	(54.10)	137.60	(51.30)
Earnings from Cont. Ops.	**345.54**	**538.80**	**643.00**	**626.50**	**933.10**	**847.70**	**480.00**	**696.00**	**352.50**	**16.80**	**(669.90)**
Extraord. Item & Account. Change	-	-	-	-	-	-	-	-	-	-	-
Minority Int. in Earnings	0.43	1.99	2.10	2.80	3.70	0.10	-	-	-	-	-
Net Income	**345.12**	**536.81**	**640.90**	**623.70**	**929.40**	**847.60**	**480.00**	**696.00**	**352.50**	**16.80**	**(669.90)**
Pref. Dividends	121.54	-	-	-	-	-	-	-	-	-	-
Other Adj	-	-	-	-	-	-	-	-	-	-	-
NI to Common Incl Extra Items	**223.58**	**536.81**	**640.90**	**623.70**	**929.40**	**847.60**	**480.00**	**696.00**	**352.50**	**16.80**	**(669.90)**
Abnormal Losses (Gains)	208.26	105.66	234.80	328.46	413.00	744.70	1,543.90	629.60	742.90	820.00	1,618.60
Tax Effect on Abnormal Items	(110.48)	(41.07)	(76.56)	(103.79)	(190.84)	(170.02)	(439.11)	(114.69)	(162.39)	(117.89)	(89.95)
NI to Common Excl. Extra Items	**321.36**	**601.39**	**799.14**	**848.37**	**1,151.56**	**1,422.28**	**1,584.79**	**1,210.91**	**933.01**	**718.91**	**858.75**
Per Share Items											
Basic EPS	0.69	1.25	1.54	1.63	2.49	1.80	0.94	1.30	0.69	0.03	(1.11)
Basic EPS Excl. Extra Items	0.69	1.25	1.54	1.63	2.49	1.80	0.94	1.30	0.69	0.03	(1.11)
Weighted Avg. Basic Shares Out.	324.45	430.84	415.20	383.30	373.70	472.20	513.00	534.50	514.50	515.70	601.20
Diluted EPS	0.68	1.22	1.52	1.58	2.34	1.70	0.92	1.30	0.68	0.03	(1.11)
Diluted EPS Excl. Extra Items	0.68	1.22	1.52	1.58	2.34	1.70	0.92	1.30	0.68	0.03	(1.11)
Weighted Avg. Diluted Shares Out.	328.98	438.79	420.20	394.50	398.00	497.40	520.50	536.70	516.50	516.50	601.20
Normalized Basic EPS	1.61	2.04	2.59	2.89	3.56	4.30	4.89	4.56	4.58	4.42	3.95
Normalized Diluted EPS	0.98	1.37	1.90	2.15	2.90	2.86	3.04	2.26	1.80	1.39	1.43
Dividends per Share	-	-	-	-	-	-	-	-	-	-	-
Payout Ratio %	-	-	-	-	-	-	-	-	-	-	-
Supplemental Items											
EBITA	1,011.87	1,363.34	1,495.80	1,499.20	1,746.40	2,306.90	1,965.20	2,955.30	2,736.00	2,566.30	1,796.30
EBIT	721.58	1,005.45	1,109.40	1,135.50	1,352.60	1,460.90	701.60	1,437.10	905.60	715.50	(210.80)
As Reported Total Revenue*	5,450.52	6,129.83	6,796.10	6,909.10	7,719.60	9,429.30	11,076.90	11,907.70	11,433.90	11,500.50	11,946.00
Effective Tax Rate %	2.92	17.69	20.04	16.16	4.25	7.40	-	22.92	-	89.12	-
Normalized Net Income	321.36	601.39	799.14	848.37	1,151.56	1,422.28	1,584.79	1,210.91	933.01	718.91	858.75
Interest Capitalized	-	-	-	-	-	-	-	-	-	-	-
Supplemental Operating Expense Items											
Net Rental Exp.	-	-	-	-	-	-	-	-	-	-	-
Stock-Based Comp., Unallocated	31.39	42.58	42.60	47.00	66.00	92.80	88.90	74.70	(3.30)	56.80	79.20
Stock-Based Comp., Total	**31.39**	**42.58**	**42.60**	**47.00**	**66.00**	**92.80**	**88.90**	**74.70**	**(3.30)**	**56.80**	**79.20**

Ticker:	vtrs US EQUITY	vtrs US EQUITY	Ascend	Currency	Reporting	Change	USD
Period Type	Annuals	Consolidated	Yes	Accounting	Mixed		

Viatris Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Balance Sheet

Balance Sheet as of:	31/12/2010	31/12/2011	31/12/2012	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
ASSETS											
Cash And Equivalents	662.05	375.06	349.97	291.30	225.50	1,236.00	998.80	292.10	388.10	475.60	844.40
Short Term Investments	29.09	30.69	-	-	-	-	83.70	76.70	25.00	26.80	39.10
Total Cash & ST Investments	**691.14**	**405.74**	**349.97**	**291.30**	**225.50**	**1,236.00**	**1,082.50**	**368.80**	**413.10**	**502.40**	**883.50**
Accounts & Notes Receivable	1,157.08	1,426.44	1,554.34	1,820.00	2,268.50	2,689.10	3,015.40	3,173.10	2,416.50	2,640.10	3,891.30
Total Receivables	**1,157.08**	**1,426.44**	**1,554.34**	**1,820.00**	**2,268.50**	**2,689.10**	**3,015.40**	**3,173.10**	**2,416.50**	**2,640.10**	**3,891.30**
Inventories	1,240.27	1,396.74	1,525.24	1,656.90	1,651.40	1,951.00	2,456.40	2,542.70	2,580.20	2,670.90	5,471.90
Prepaid Exp.	188.25	127.75	243.82	452.90	2,295.80	596.60	756.40	766.10	518.40	552.00	1,707.40
Restricted Cash	23.97	9.27	-	-	-	-	-	-	-	-	-
Other Current Assets	258.73	202.90	229.35	250.10	-	-	211.80	362.60	439.50	391.90	913.40
Total Current Assets	**3,559.44**	**3,568.84**	**3,902.72**	**4,471.20**	**6,441.20**	**6,472.70**	**7,522.50**	**7,213.30**	**6,367.70**	**6,757.30**	**12,867.50**
Net Property, Plant & Equipment	**1,209.34**	**1,298.03**	**1,397.22**	**1,665.50**	**1,785.70**	**1,983.90**	**2,322.20**	**2,339.10**	**2,170.20**	**2,404.20**	**3,783.50**
Long-term Investments	-	-	-	-	-	-	-	-	-	-	-
Deferred Charges, LT	58.28	39.38	87.66	77.80	397.40	457.60	633.20	496.80	572.20	703.10	2,147.90
Other Long-Term Assets	6,709.74	6,691.89	6,544.31	9,080.30	7,196.20	13,353.50	24,248.30	25,757.10	23,624.80	21,390.90	42,754.10
Total Assets	**11,536.80**	**11,598.14**	**11,931.90**	**15,294.80**	**15,820.50**	**22,267.70**	**34,726.20**	**35,806.30**	**32,734.90**	**31,255.50**	**61,553.00**
LIABILITIES											
Accrued Exp.	-	-	-	-	-	-	-	-	-	-	-
Short-term Borrowings	169.77	819.67	397.04	443.40	2,803.60	1,078.30	336.40	1,855.40	701.70	1,584.80	3,502.30
Accounts Payable	564.71	703.24	777.91	1,072.80	905.60	1,109.60	1,348.10	1,452.50	1,617.00	1,528.10	1,904.20
Curr. Income Taxes Payable	15.11	42.88	33.73	49.70	160.70	92.40	97.70	112.90	121.50	213.00	288.60
Other Current Liabilities	1,060.03	997.37	984.83	1,398.10	1,434.10	1,841.90	3,258.50	2,964.50	2,147.60	2,243.20	4,867.80
Total Current Liabilities	**1,809.61**	**2,563.16**	**2,193.50**	**2,964.00**	**5,304.00**	**4,122.20**	**5,040.70**	**6,385.30**	**4,587.80**	**5,569.10**	**10,562.90**
Long-Term Debt	4,790.98	4,019.08	4,700.90	7,586.50	3,846.40	6,295.60	15,202.90	12,865.30	13,161.20	11,390.00	22,658.70
Unearned Revenue, Non-Current	-	-	-	-	-	-	-	-	-	-	-
Other Non-Current Liabilities	1,320.82	1,511.13	1,681.67	1,784.40	3,394.10	2,084.10	3,365.00	3,248.10	2,818.80	2,412.60	5,377.30
Total Liabilities	**7,921.40**	**8,093.36**	**8,576.07**	**12,334.90**	**12,544.50**	**12,501.90**	**23,608.60**	**22,498.70**	**20,567.80**	**19,371.70**	**38,598.90**
Pref. Stock, Non-Redeem.	-	-	-	-	-	-	-	-	-	-	-
Total Pref. Equity	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**
Minority Interest	13.52	13.01	15.11	18.10	20.10	1.40	1.40	-	-	-	-
Additional Paid In Capital	4,112.59	4,060.53	4,256.58	4,375.60	4,486.10	7,134.10	8,505.30	8,592.00	8,597.40	8,649.60	18,450.90
Retained Earnings	883.71	1,420.52	2,061.37	2,685.10	3,614.50	4,462.10	4,942.10	5,644.50	6,010.70	6,031.10	5,361.20
Treasury Stock	(1,566.29)	(1,901.44)	(2,890.73)	(3,878.80)	(3,857.70)	(67.50)	(67.50)	(567.70)	(999.70)	(999.70)	-
Comprehensive Inc. and Other	171.87	(87.84)	(86.50)	(240.10)	(987.00)	(1,764.30)	(2,263.70)	(361.20)	(1,441.30)	(1,797.20)	(858.00)
Total Common Equity	**3,615.40**	**3,504.78**	**3,355.83**	**2,959.90**	**3,276.00**	**9,765.80**	**11,117.60**	**13,307.60**	**12,167.10**	**11,883.80**	**22,954.10**
Total Equity	**3,615.40**	**3,504.78**	**3,355.83**	**2,959.90**	**3,276.00**	**9,765.80**	**11,117.60**	**13,307.60**	**12,167.10**	**11,883.80**	**22,954.10**
Total Liabilities And Equity	**11,536.80**	**11,598.14**	**11,931.90**	**15,294.80**	**15,820.50**	**22,267.70**	**34,726.20**	**35,806.30**	**32,734.90**	**31,255.50**	**61,553.00**
Supplemental Items											
Total Shares Out. on Filing Date	436.11	426.68	395.21	371.60	375.22	490.62	535.33	524.21	515.80	516.15	1,206.90
Total Shares Out. on Balance Sheet Date	436.11	426.68	395.21	371.60	375.22	490.62	535.33	524.21	515.80	516.15	1,206.90
Book Value/Share	8.26	8.18	8.45	7.92	8.68	19.90	20.77	25.39	23.59	23.02	19.02
Tangible Book Value	(2,498.61)	(2,656.91)	(2,399.39)	(3,916.60)	(3,140.50)	(2,837.60)	(12,563.50)	(12,143.90)	(11,245.30)	(9,356.70)	(19,076.10)
Tangible Book Value/Share	(5.73)	(6.23)	(6.07)	(10.54)	(8.37)	(5.78)	(23.47)	(23.17)	(21.80)	(18.13)	(15.81)
Total Debt	4,960.75	4,838.75	5,097.93	8,029.90	6,650.00	7,373.90	15,539.30	14,720.70	13,862.90	12,974.80	26,161.00
Net Debt	4,269.61	4,433.01	4,747.96	7,738.60	6,424.50	6,137.90	14,456.80	14,351.90	13,449.80	12,472.40	25,277.50
Total Minority Interest	13.52	13.01	15.11	18.10	20.10	1.40	1.40	-	-	-	-
Inventory Method	--	--	--	--	--	--	--	--	--	--	--
Raw Materials in Inventory	337.09	370.42	455.96	482.80	549.50	592.40	783.40	895.50	955.70	886.80	958.40
Work in Progress Inventory	230.24	253.49	268.19	310.00	298.40	387.00	436.00	384.70	369.90	417.20	1,438.10
Finished Goods Inventory	672.94	772.83	801.09	864.10	803.50	971.60	1,237.00	1,262.50	1,254.60	1,366.90	3,075.40
Other Inventory Accounts	-	-	-	-	-	-	-	-	-	-	-
Accum. Allowance for Doubtful Accts	23.90	18.93	23.04	24.60	25.70	33.60	59.00	75.30	98.20	72.80	159.90
Full Time Employees	-	-	-	20,000.00	30,000.00	35,000.00	35,000.00	35,000.00	35,000.00	35,000.00	45,000.00

Bloomberg

Company In Depth Fundamentals - Cash Flow Statement

Ticker:	vtrs US EQUITY	Sort	Ascend	Currency Selection	Reporting	Change	USD
Period Type	Annuals	Consolidated	Yes	Accounting Standard	Mixed		

Viatris Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Cash Flow

For the Fiscal Period Ending	31/12/2010	31/12/2011	31/12/2012	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020
Currency	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*
Net Income	**345.12**	**536.81**	**640.90**	**623.70**	**929.40**	**847.60**	**480.00**	**696.00**	**352.50**	**16.80**	**(669.90)**
Depreciation & Amort., Total	**422.79**	**510.69**	**546.60**	**516.00**	**566.60**	**1,032.10**	**1,523.00**	**1,805.80**	**2,109.90**	**2,019.30**	**2,216.10**
Other Non-Cash Adj	169.47	(17.21)	434.20	455.60	(180.70)	415.80	330.10	(174.90)	(109.60)	338.90	427.90
Changes in Non-Cash Capital	(5.97)	(309.87)	(672.70)	(488.70)	(300.50)	(287.00)	(285.90)	(262.10)	(11.10)	(571.30)	(742.30)
Cash from Ops.	**931.40**	**720.42**	**949.00**	**1,106.60**	**1,014.80**	**2,008.50**	**2,047.20**	**2,064.80**	**2,341.70**	**1,803.70**	**1,231.80**
Capital Expenditure	(192.79)	(279.85)	(305.30)	(334.60)	(325.30)	(362.90)	(390.40)	(275.90)	(252.10)	(213.20)	(243.00)
Sale of Property, Plant, and Equipment	-	-	16.30	25.30	-	-	-	-	-	-	2.10
Cash Acquisitions	-	-	-	-	-	-	-	-	-	-	-
Proceeds from Investment	-	-	-	-	-	-	-	-	-	-	-
Divestitures	-	-	-	-	-	-	-	-	-	-	415.80
Invest. in Marketable & Equity Securt.	-	-	-	-	-	-	-	-	-	-	-
Other Investing Activities	(532.62)	(52.19)	(75.20)	(1,559.50)	(475.00)	(1,206.80)	(7,230.30)	(700.50)	(958.30)	(312.20)	(476.00)
Cash from Investing	**(725.41)**	**(332.04)**	**(364.20)**	**(1,868.80)**	**(800.30)**	**(1,569.70)**	**(7,620.70)**	**(976.40)**	**(1,210.40)**	**(525.40)**	**(301.10)**
Net Short Term Debt Issued/Repaid	(27.42)	(15.61)	174.30	141.40	(107.80)	(329.20)	40.80	(2.90)	(44.40)	(1.80)	1,099.60
Long-Term Debt Issued	2,356.63	1,458.00	2,043.40	4,974.70	2,235.00	5,510.00	11,752.20	876.10	2,577.90	7.40	983.30
Long-Term Debt Repaid	(2,115.40)	(1,644.20)	(1,990.80)	(3,480.30)	(2,295.80)	(4,484.10)	(6,296.30)	(2,232.70)	(3,165.20)	(1,108.50)	(2,484.20)
Total Debt Issued/Repaid	**213.82**	**(201.81)**	**226.90**	**1,635.80**	**(168.60)**	**696.70**	**5,496.70**	**(1,359.50)**	**(631.70)**	**(1,102.90)**	**(401.30)**
Pref. Dividends Paid	(139.04)	-	-	-	-	-	-	-	-	-	-
Total Dividends Paid	**(139.04)**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**
Increase in Capital Stocks	54.65	67.74	143.80	76.20	53.80	97.70	13.80	17.80	17.80	8.10	0.60
Decrease in Capital Stocks	-	(350.00)	(999.90)	(1,000.00)	-	(67.50)	-	(500.20)	(432.00)	-	-
Special Dividend Paid	-	-	-	-	-	-	-	-	-	-	-
Incr(Decr) in Deposits	-	-	-	-	-	-	-	-	-	-	-
Incr(Decr) Insurance Reserves	-	-	-	-	-	-	-	-	-	-	-
Other Financing Activities	(53.89)	(191.31)	19.30	(8.50)	(165.50)	(155.20)	(174.20)	(23.60)	(66.00)	(81.70)	(171.20)
Cash from Financing	**75.54**	**(675.38)**	**(609.90)**	**703.50**	**(280.30)**	**571.70**	**5,336.30**	**(1,865.50)**	**(1,111.90)**	**(1,176.50)**	**(571.90)**
Net Change in Cash	**281.54**	**(287.00)**	**(25.10)**	**(58.70)**	**(65.80)**	**1,010.50**	**(237.20)**	**(777.10)**	**19.40**	**101.80**	**358.80**
Supplemental Items											
Cash Interest Paid	144.18	284.64	246.80	249.40	273.80	254.70	357.20	474.00	460.80	470.60	555.40
Cash Taxes Paid	114.81	124.12	308.50	189.60	210.50	302.90	285.60	285.70	228.60	278.60	324.40
Free Cash Flow	738.61	440.58	643.70	772.00	689.50	1,645.60	1,656.80	1,788.90	2,089.60	1,590.50	988.80
Change in Net Working Capital	-	-	-	-	-	-	-	-	-	-	-

Bloomberg

Company In Depth Fundamentals - Multiples

Ticker:	vtrs US EQUITY	Sort	Ascend		
Period Type	Annuals	Consolidated	Yes	Accounting	Mixed

Viatris Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Multiples

		31/12/2010	31/12/2011	31/12/2012	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020
TEV / LTM Total Revenue	**Close**	**2.5x**	**2.2x**	**2.3x**	**3.5x**	**3.6x**	**3.5x**	**3.1x**	**3.1x**	**2.4x**	**2.0x**	**4.0x**
	Average	1.9x	2.5x	2.3x	2.6x	3.8x	4.4x	3.0x	3.1x	2.9x	2.2x	2.0x
	High	2.5x	2.8x	2.6x	3.5x	4.3x	5.7x	3.5x	3.5x	3.4x	2.6x	4.0x
	Low	1.7x	2.0x	2.2x	2.3x	3.5x	3.3x	2.6x	2.7x	2.3x	1.9x	1.7x
TEV / LTM EBITDA	**Close**	**11.8x**	**9.0x**	**9.4x**	**14.5x**	**14.4x**	**13.1x**	**15.7x**	**11.3x**	**9.1x**	**8.1x**	**23.0x**
	Average	10.4x	11.9x	9.4x	10.8x	16.0x	17.6x	11.4x	15.6x	10.5x	8.3x	8.1x
	High	13.7x	13.4x	10.5x	14.8x	18.0x	22.8x	15.7x	17.4x	12.3x	9.9x	23.0x
	Low	9.3x	9.0x	8.8x	9.3x	14.4x	13.1x	9.8x	11.4x	8.6x	7.3x	6.8x
TEV / LTM EBIT	**Close**	**18.7x**	**13.5x**	**14.1x**	**21.0x**	**20.4x**	**22.4x**	**49.7x**	**25.4x**	**30.5x**	**31.5x**	**--**
	Average	18.4x	18.8x	14.1x	16.1x	23.3x	25.0x	19.6x	49.3x	23.7x	27.6x	31.2x
	High	24.2x	21.2x	15.9x	21.5x	26.2x	32.3x	49.7x	55.2x	30.5x	33.1x	47.6x
	Low	16.3x	13.5x	13.2x	13.9x	20.4x	19.0x	16.7x	25.8x	19.4x	24.4x	26.6x
Price / LTM EPS	**Close**	**21.6x**	**15.7x**	**14.5x**	**20.2x**	**19.5x**	**18.9x**	**12.5x**	**18.7x**	**15.2x**	**14.5x**	**13.1x**
	Average	24.9x	22.0x	17.0x	17.9x	23.2x	20.0x	15.2x	12.4x	16.8x	12.4x	12.2x
	High	29.9x	25.8x	20.7x	23.5x	27.3x	26.2x	18.9x	18.7x	21.1x	17.8x	16.4x
	Low	21.6x	15.7x	14.5x	14.5x	19.5x	13.5x	12.0x	9.7x	11.6x	9.3x	9.5x
Price / Book Value	**Close**	**2.6x**	**2.6x**	**3.2x**	**5.5x**	**6.5x**	**2.7x**	**1.8x**	**1.7x**	**1.2x**	**0.9x**	**1.0x**
	Average	1.9x	2.6x	2.8x	4.0x	6.3x	6.7x	2.2x	1.8x	1.5x	0.9x	0.7x
	High	2.6x	3.1x	3.5x	5.5x	7.4x	8.8x	2.7x	2.2x	1.9x	1.4x	1.0x
	Low	1.7x	2.0x	2.5x	3.3x	5.3x	2.7x	1.7x	1.4x	1.0x	0.7x	0.6x
Price / Tangible Book Value	**Close**	**--**	**--**	**--**	**--**	**--**	**--**	**--**	**--**	**--**	**--**	**--**
	Average	--	--	--	--	--	--	--	--	--	--	--
	High	--	--	--	--	--	--	--	--	--	--	--
	Low	--	--	--	--	--	--	--	--	--	--	--
Price / Cash Flow	**Close**	**7.4x**	**12.8x**	**12.0x**	**15.0x**	**20.8x**	**12.7x**	**9.6x**	**11.0x**	**6.0x**	5.7x	**9.1x**
	Average	9.8x	7.5x	13.9x	14.8x	17.3x	21.3x	10.2x	9.4x	9.8x	4.9x	4.8x
	High	11.7x	12.8x	16.9x	19.5x	20.8x	28.0x	12.7x	11.3x	12.3x	7.1x	9.1x
	Low	7.4x	5.6x	12.0x	12.0x	14.6x	12.7x	8.0x	7.4x	6.0x	3.7x	3.8x
TEV / LTM FCF	**Close**	**9.3x**	**21.0x**	**17.7x**	**21.5x**	**30.6x**	**15.5x**	**11.8x**	**12.6x**	**6.7x**	**6.5x**	**11.4x**
	Average	13.1x	9.5x	22.8x	21.8x	24.8x	31.3x	12.5x	11.7x	11.3x	5.5x	5.5x
	High	15.7x	21.0x	27.7x	28.7x	30.6x	41.2x	15.5x	14.0x	14.2x	7.9x	11.4x
	Low	9.3x	7.1x	17.7x	17.8x	21.0x	15.5x	9.8x	9.2x	6.7x	4.1x	4.3x
Dividend Yield	**Close**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**
	Average	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	High	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	Low	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Ticker:	vtrs US EQUITY	vtrs US EQUITY	Ascend		
Period Type	Quarters	Consolidated	Yes	Accounting	Mixed

Viatris Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Ratios											
For the Fiscal Period Ending	31/03/2019	30/06/2019	30/09/2019	31/12/2019	31/03/2020	30/06/2020	30/09/2020	31/12/2020	31/03/2021	30/06/2021	30/09/2021
Profitability											
Return on Assets	0.7%	0.1%	0.1%	0.1%	0.2%	0.9%	0.9%	-1.4%	-3.9%	-4.6%	-4.4%
Return on Capital	2.5%	0.8%	1.2%	0.3%	0.7%	2.5%	2.3%	-0.7%	-3.7%	-4.5%	-4.1%
Return on Equity	1.9%	0.3%	0.4%	0.1%	0.5%	2.3%	2.2%	-3.8%	-10.6%	-12.4%	-11.4%
Margin Analysis											
Gross Margin	32.3%	32.7%	36.2%	34.1%	34.6%	37.6%	39.0%	19.5%	25.4%	29.0%	34.7%
SG&A Margin	22.6%	22.0%	19.5%	18.5%	21.5%	20.3%	19.1%	--	21.2%	20.8%	21.2%
EBITDA Margin	25.9%	25.0%	24.6%	24.3%	24.5%	24.4%	24.1%	16.8%	18.6%	21.0%	22.6%
EBIT Margin	6.9%	6.1%	5.9%	6.2%	7.5%	8.0%	8.2%	-1.8%	-4.8%	-5.4%	-4.9%
Earnings from Cont. Ops Margin	1.0%	3.3%	10.9%	8.5%	7.1%	4.9%	11.8%	-24.3%	-6.0%	-1.0%	7.9%
Net Income Margin	-1.0%	-5.9%	6.4%	0.6%	0.8%	1.4%	6.2%	-25.3%	-23.4%	-6.1%	6.9%
Normalized Net Income Margin	3.8%	3.8%	9.3%	8.1%	6.0%	10.1%	12.9%	1.0%	-9.0%	6.3%	17.8%
Free Cash Flow Margin	-3.7%	21.9%	15.0%	18.4%	9.5%	12.3%	16.4%	-2.2%	18.0%	10.3%	21.3%
Asset Turnover											
Total Asset Turnover	0.3x	0.3x	0.4x	0.4x	0.4x	0.4x	0.4x	0.3x	0.3x	0.4x	0.4x
Fixed Asset Turnover	4.8x	4.9x	5.4x	5.0x	5.0x	4.9x	5.2x	3.9x	4.7x	5.4x	6.0x
Accounts Receivable Turnover	4.6x	4.7x	4.4x	4.5x	4.8x	4.9x	4.5x	3.7x	4.4x	4.9x	5.3x
Inventory Turnover	2.8x	2.8x	2.8x	2.9x	2.9x	2.7x	2.5x	2.0x	2.6x	3.1x	3.5x
Short Term Liquidity											
Current Ratio	1.5x	1.4x	1.4x	1.2x	1.3x	0.9x	1.0x	1.2x	1.2x	1.2x	1.1x
Quick Ratio	0.6x	0.6x	0.6x	0.6x	0.6x	0.4x	0.5x	0.5x	0.5x	0.5x	0.5x
Cash from Ops. To Curr Liab	0.1x	0.1x	0.1x	0.1x	0.1x	0.1x	0.1x	0.1x	0.1x	0.1x	0.1x
Avg. Days Sales Out.	79.9x	76.8x	82.3x	80.2x	75.5x	75.0x	81.6x	100.1x	83.8x	73.9x	68.3x
Avg. Days Inventory Out.	131.5x	129.9x	128.5x	126.0x	128.3x	137.3x	144.3x	182.9x	142.1x	117.6x	104.3x
Avg. Days Payable Out.	65.9x	68.2x	68.5x	74.6x	62.7x	68.9x	71.3x	57.4x	50.3x	43.0x	42.0x
Avg. Cash Conversion Cycle	145.6x	138.6x	142.4x	131.7x	141.1x	143.4x	154.6x	225.5x	175.6x	148.6x	130.6x
Long Term Solvency											
Total Debt/Equity	117.9%	114.2%	116.2%	109.2%	114.7%	105.7%	100.1%	114.0%	115.6%	116.5%	112.2%
Total Debt/Capital	54.1%	53.3%	53.8%	52.2%	53.4%	51.4%	50.0%	53.3%	53.6%	53.8%	52.9%
LT Debt/Equity	111.3%	107.2%	110.3%	95.8%	100.9%	77.9%	73.8%	98.7%	104.2%	99.6%	94.9%
LT Debt/Capital	51.1%	50.1%	51.0%	45.8%	47.0%	37.9%	36.9%	46.1%	48.3%	46.0%	44.7%
Total Liabilities/Total Assets	49.7%	48.3%	48.1%	44.2%	45.3%	37.9%	36.6%	45.5%	46.8%	46.0%	44.3%
EBIT / Interest Exp.	0.18x	0.73x	2.51x	2.16x	1.54x	1.15x	3.00x	-6.10x	-1.58x	-0.29x	2.35x
EBITDA / Interest Exp.	4.18x	4.55x	6.32x	6.67x	5.00x	4.73x	6.68x	0.50x	6.84x	7.60x	9.05x
(EBITDA-CAPEX) / Interest Exp.	3.78x	4.21x	5.99x	5.89x	4.64x	4.35x	6.36x	-0.31x	6.55x	7.06x	8.25x
Total Debt/EBITDA	4.70x	4.81x	4.73x	4.63x	4.53x	4.43x	4.53x	13.05x	9.66x	7.53x	6.13x
Net Debt/EBITDA	4.62x	4.72x	4.59x	4.45x	4.32x	4.30x	4.28x	12.61x	9.33x	7.31x	5.92x
Altman Z Score	3.08	2.83	2.8	2.69	2.77	2.59	2.49	1.46	1.37	1.4	1.56
Growth Over Prior Year											
Total Revenue	(7.0%)	1.5%	3.5%	3.7%	5.0%	(4.2%)	0.4%	13.5%	69.1%	67.6%	52.6%
Gross Profit	(18.2%)	(3.1%)	3.2%	7.1%	12.5%	10.0%	8.0%	(35.0%)	24.4%	29.4%	35.9%
EBITDA	(16.1%)	(12.3%)	(2.9%)	(0.2%)	9.3%	(7.9%)	(3.8%)	(91.4%)	92.8%	130.8%	75.4%
EBITA	(21.5%)	(12.0%)	0.0%	20.2%	18.1%	(9.3%)	(4.1%)	(103.3%)	(22.0%)	30.5%	43.0%
EBIT	(84.6%)	(46.6%)	(4.3%)	17.0%	669.6%	40.5%	8.6%	(423.6%)	(244.1%)	(135.6%)	1.8%
Earnings from Cont. Ops.	(128.7%)	(549.3%)	7.4%	(60.0%)	(183.2%)	(123.4%)	(2.2%)	(4,567.3%)	(5,088.5%)	(808.6%)	67.7%
Net Income	(128.7%)	(549.3%)	7.4%	(60.0%)	(183.2%)	(123.4%)	(2.2%)	(4,567.3%)	(5,088.5%)	(808.6%)	67.7%
Normalized Net Income	(53.5%)	(49.7%)	(57.7%)	24.2%	64.2%	154.5%	38.9%	(85.9%)	(354.9%)	4.7%	111.9%
Diluted EPS before Extra	(129.4%)	(571.4%)	8.8%	(60.0%)	(180.0%)	(124.2%)	(2.7%)	(2,779.0%)	(2,250.0%)	(387.5%)	(27.8%)
Accounts Receivable	(7.4%)	(8.1%)	(1.7%)	9.3%	2.6%	7.2%	1.6%	47.4%	60.1%	59.0%	48.4%
Inventory	2.6%	8.4%	7.9%	3.5%	(2.6%)	0.3%	9.4%	104.9%	87.2%	61.1%	35.1%
Net PP&E	4.9%	9.6%	0.2%	10.8%	(3.5%)	(5.4%)	7.6%	57.4%	54.5%	53.1%	49.6%
Total Assets	(9.3%)	(4.4%)	(7.2%)	(4.5%)	(5.5%)	(5.2%)	0.6%	96.9%	95.6%	92.3%	79.5%
Tangible Book Value	(12.6%)	(11.1%)	(18.6%)	(16.9%)	(14.7%)	(17.2%)	(15.7%)	(12.8%)	(10.9%)	(8.7%)	(6.5%)
Common Equity	(9.8%)	(2.5%)	(5.0%)	(2.3%)	(5.3%)	(1.3%)	9.5%	93.2%	90.1%	80.5%	68.5%
Cash from Ops.	(106.4%)	55.5%	(25.4%)	8.0%	(833.2%)	(43.3%)	7.6%	(94.7%)	191.6%	47.4%	106.8%
Capital Expenditures	73.0%	(2.0%)	(31.4%)	(14.6%)	(18.3%)	0.5%	(9.5%)	19.4%	14.1%	100.7%	216.8%
Levered Free Cash Flow	(115.7%)	62.2%	(24.7%)	12.9%	(366.9%)	(46.4%)	9.2%	(113.7%)	222.7%	40.3%	98.2%
Unlevered Free Cash Flow	(115.7%)	62.2%	(24.7%)	12.9%	(366.9%)	(46.4%)	9.2%	(113.7%)	222.7%	0.6%	70.8%
Dividend per Share	--	--	--	--	--	--	--	--	--	--	--

CAGR Over Two Years											
Total Revenue	(4.2%)	(1.9%)	(0.4%)	(0.7%)	(1.2%)	(1.4%)	1.9%	8.5%	33.2%	26.7%	23.8%
Gross Profit	(13.9%)	(12.8%)	(4.6%)	(8.4%)	(4.1%)	3.2%	5.6%	(16.6%)	18.3%	19.3%	21.2%
EBITDA	(7.6%)	(18.3%)	3.6%	(5.8%)	(4.3%)	(10.1%)	(3.3%)	(70.8%)	45.2%	45.8%	29.9%
EBITA	(10.8%)	(19.6%)	4.6%	(5.8%)	(3.7%)	(10.6%)	(2.1%)	--	(4.0%)	8.8%	17.1%
EBIT	(67.5%)	(55.1%)	1.1%	(19.5%)	8.9%	(13.4%)	1.9%	--	--	--	5.1%
Earnings from Cont. Ops.	--	--	46.6%	(71.0%)	(51.1%)	2.5%	2.5%	--	544.2%	28.7%	28.1%
Net Income	--	--	46.6%	(71.0%)	(51.1%)	2.5%	2.5%	--	544.2%	28.7%	28.1%
Normalized Net Income	(32.9%)	(43.0%)	7.6%	(31.2%)	(12.6%)	13.1%	(23.3%)	(58.1%)	--	63.3%	71.5%
Diluted EPS before Extra	--	--	52.1%	(70.5%)	(51.5%)	6.9%	2.9%	--	314.7%	(16.5%)	(16.2%)
Accounts Receivable	(9.2%)	(12.2%)	(11.1%)	(8.8%)	(2.5%)	(0.7%)	(0.1%)	26.9%	28.2%	30.6%	22.8%
Inventory	3.1%	3.1%	4.1%	2.5%	(0.0%)	4.3%	8.6%	45.6%	35.1%	27.1%	21.5%
Net PP&E	1.1%	0.6%	(4.1%)	1.4%	0.6%	1.8%	3.9%	32.0%	22.1%	20.4%	26.9%
Total Assets	(3.5%)	(5.3%)	(6.9%)	(6.6%)	(7.4%)	(4.8%)	(3.4%)	37.1%	36.0%	35.0%	34.4%
Tangible Book Value	(4.4%)	(5.2%)	(8.0%)	(11.5%)	(13.7%)	(14.2%)	(17.2%)	(14.9%)	(12.8%)	(13.0%)	(11.2%)
Common Equity	1.0%	(3.7%)	(7.1%)	(5.5%)	(7.5%)	(1.9%)	2.0%	37.4%	34.2%	33.5%	35.8%
Cash from Ops.	--	8.5%	(5.7%)	17.7%	(31.6%)	(6.1%)	(10.4%)	(76.1%)	--	(8.6%)	49.2%
Capital Expenditures	(4.6%)	(6.7%)	(5.3%)	(19.4%)	18.9%	(0.8%)	(21.2%)	1.0%	(3.4%)	42.0%	69.3%
Levered Free Cash Flow	--	9.9%	(5.7%)	30.7%	(35.3%)	(6.7%)	(9.3%)	--	--	(13.2%)	47.1%
Unlevered Free Cash Flow	--	9.9%	(5.7%)	30.7%	(35.3%)	(6.7%)	(9.3%)	--	--	(26.5%)	36.6%
Dividend per Share	--	--	--	--	--	--	--	--	--	--	--
CAGR Over Three Years											
Total Revenue	4.4%	3.7%	(1.1%)	(0.8%)	(1.2%)	(2.7%)	(0.2%)	3.8%	18.2%	17.7%	16.6%
Gross Profit	(3.9%)	(7.3%)	(5.8%)	(6.6%)	(5.8%)	(5.8%)	(0.6%)	(18.3%)	4.6%	11.3%	14.8%
EBITDA	10.9%	(16.1%)	37.2%	2.0%	(2.3%)	(15.0%)	1.0%	(57.6%)	20.9%	23.1%	17.9%
EBITA	15.7%	(8.9%)	47.6%	2.2%	(2.0%)	(16.3%)	1.6%	(130.8%)	(10.2%)	1.4%	11.1%
EBIT	(39.0%)	(38.5%)	(235.3%)	(4.8%)	(6.7%)	(34.3%)	3.5%	(228.0%)	(219.6%)	(164.4%)	1.9%
Earnings from Cont. Ops.	(221.6%)	(200.0%)	(216.6%)	(63.4%)	(32.1%)	(49.0%)	28.1%	(255.3%)	(328.4%)	(295.3%)	20.8%
Net Income	(221.6%)	(200.0%)	(216.6%)	(63.4%)	(32.1%)	(49.0%)	28.1%	(255.3%)	(328.4%)	(295.3%)	20.8%
Normalized Net Income	(18.2%)	(38.7%)	(19.3%)	(27.4%)	(9.5%)	(6.1%)	17.2%	(59.4%)	(224.8%)	10.3%	7.6%
Diluted EPS before Extra	(218.6%)	(200.0%)	(217.2%)	(62.8%)	(30.7%)	(47.4%)	31.0%	(232.6%)	(271.7%)	(248.7%)	(8.6%)
Accounts Receivable	(2.9%)	(7.9%)	(6.3%)	(4.3%)	(5.4%)	(6.1%)	(7.0%)	7.0%	15.0%	16.1%	14.0%
Inventory	8.1%	8.2%	0.9%	2.8%	1.2%	2.2%	5.9%	29.1%	23.2%	20.6%	16.8%
Net PP&E	6.1%	5.2%	(2.4%)	1.2%	(0.5%)	(1.4%)	(0.3%)	17.4%	16.1%	16.7%	17.3%
Total Assets	12.1%	3.3%	(5.3%)	(3.4%)	(4.2%)	(5.3%)	(4.5%)	19.8%	18.8%	20.3%	18.8%
Tangible Book Value	58.0%	47.7%	(9.0%)	(8.2%)	(7.9%)	(9.4%)	(10.6%)	(12.0%)	(12.8%)	(12.4%)	(13.7%)
Common Equity	5.0%	4.8%	(1.0%)	2.3%	(1.1%)	(2.9%)	(1.9%)	19.9%	17.6%	20.2%	20.6%
Cash from Ops.	(179.0%)	10.4%	(25.9%)	25.2%	(13.7%)	(12.6%)	(1.5%)	(58.2%)	10.9%	9.1%	18.4%
Capital Expenditures	0.8%	(38.5%)	(29.1%)	(13.4%)	(9.4%)	(4.4%)	(6.7%)	(8.1%)	17.3%	25.5%	25.3%
Levered Free Cash Flow	(247.9%)	26.7%	(25.6%)	43.7%	(14.4%)	(13.5%)	(1.0%)	(161.6%)	10.6%	6.9%	17.7%
Unlevered Free Cash Flow	(247.9%)	26.7%	(25.6%)	43.7%	(14.4%)	(13.5%)	(1.0%)	(161.6%)	10.6%	(4.3%)	12.0%
Dividend per Share	--	--	--	--	--	--	--	--	--	--	--
CAGR Over Five Years											
Total Revenue	7.8%	9.2%	7.3%	8.9%	7.0%	2.9%	2.0%	7.8%	15.1%	12.3%	8.2%
Gross Profit	1.8%	2.9%	1.2%	2.3%	1.8%	0.3%	(2.5%)	(7.8%)	4.4%	2.5%	4.2%
EBITDA	8.0%	10.9%	5.3%	8.4%	12.4%	0.5%	(1.8%)	(37.7%)	23.5%	4.6%	34.3%
EBITA	5.8%	11.4%	4.9%	(0.3%)	12.1%	(1.5%)	(2.5%)	(151.4%)	7.4%	(2.2%)	34.5%
EBIT	(36.9%)	(15.8%)	(8.1%)	(7.1%)	3.0%	(13.5%)	(10.2%)	(215.8%)	(220.3%)	(165.0%)	(222.3%)
Earnings from Cont. Ops.	(173.5%)	(205.9%)	(17.6%)	(36.0%)	(18.1%)	(25.2%)	(15.4%)	(236.3%)	(336.9%)	(210.6%)	(221.1%)
Net Income	(173.6%)	(206.1%)	(17.6%)	(35.9%)	(18.1%)	(25.2%)	(15.4%)	(236.3%)	(336.9%)	(210.6%)	(221.1%)
Normalized Net Income	(11.5%)	(10.7%)	(7.2%)	(3.0%)	(3.8%)	(0.4%)	(6.7%)	(35.5%)	(218.0%)	(9.3%)	9.1%
Diluted EPS before Extra	(170.4%)	(200.6%)	(21.7%)	(38.9%)	(21.0%)	(24.2%)	(15.4%)	(223.0%)	(295.6%)	(193.0%)	(202.5%)
Accounts Receivable	7.1%	5.3%	8.0%	3.1%	1.4%	(3.1%)	(2.4%)	7.7%	8.5%	5.9%	4.4%
Inventory	9.3%	9.2%	10.1%	10.1%	6.7%	7.6%	9.2%	22.9%	18.2%	15.4%	8.7%
Net PP&E	7.0%	6.4%	4.1%	6.1%	4.2%	3.6%	3.9%	13.8%	12.2%	11.0%	8.4%
Total Assets	15.8%	15.3%	15.4%	14.6%	6.4%	5.8%	7.9%	22.6%	21.1%	15.0%	8.9%
Tangible Book Value	16.2%	17.0%	16.2%	16.7%	25.1%	27.4%	28.9%	22.3%	24.6%	19.5%	(9.9%)
Common Equity	30.2%	29.0%	27.6%	29.6%	4.4%	4.2%	5.0%	18.6%	15.8%	15.5%	12.3%
Cash from Ops.	(168.2%)	30.1%	2.1%	40.2%	1.7%	27.0%	(11.6%)	(43.9%)	60.2%	2.4%	(2.0%)
Capital Expenditures	(6.0%)	(11.4%)	(8.8%)	(3.0%)	(2.0%)	(9.6%)	(14.8%)	(5.6%)	(0.9%)	(14.0%)	0.4%
Levered Free Cash Flow	(186.1%)	44.7%	3.6%	115.1%	2.5%	52.4%	(11.4%)	(169.5%)	94.5%	8.9%	(2.3%)
Unlevered Free Cash Flow	(186.1%)	44.7%	3.6%	115.1%	2.5%	52.4%	(11.4%)	(169.5%)	94.5%	1.9%	(5.1%)
Dividend per Share	--	--	--	--	--	--	--	--	--	--	--

Bloomberg

Company In Depth Fundamentals - Capital Structure Summary

Ticker:	vtrs US EQUITY	Sort	Ascend	Currency	Reporting	Change	USD
Period Type	Quarters	Consolidated	Yes	Accounting	Mixed		

Viatris Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

WACC

For the Fiscal Period Ending	30/09/2020	31/12/2020	31/03/2021	30/06/2021	30/09/2021
	%	%	%	%	%
Equity					
Cost of Equity	8.4%	7.9%	9.0%	9.0%	9.4%
Weight of Equity	37.9%	46.4%	40.6%	41.2%	40.9%
+ Debt					
Cost of Debt	0.5%	1.2%	2.3%	1.9%	1.9%
Weight of Debt	62.1%	53.6%	59.4%	58.8%	59.1%
+ Preferred Equity					
Cost of Pref Equity	--	--	--	--	--
Weight of Pref Equity	0.0%	0.0%	0.0%	0.0%	0.0%
WACC	**3.5%**	**4.3%**	**5.0%**	**4.8%**	**5.0%**

Capital Structure

For the Fiscal Period Ending	30/09/2020		31/12/2020		31/03/2021		30/06/2021		30/09/2021	
Currency	*USD*		*USD*		*USD*		*USD*		*USD*	
	Millions	*% of Total*	*Millions*	*% of Total*	*Millions*	*% of Total*	*Millions*	*% of Total*	*Millions*	*% of Total*
Hist Market Cap	7,666.4	*37.9%*	22,617.2	*46.4%*	16,883.2	*40.6%*	17,279.6	*41.2%*	16,387.1	*40.9%*
ST Borrowings	3,306.6	*16.3%*	3,502.3	*7.2%*	2,429.0	*5.8%*	3,574.4	*8.5%*	3,656.8	*9.1%*
LT Borrowings	9,258.4	*45.8%*	22,658.7	*46.5%*	22,319.4	*53.6%*	21,125.6	*50.3%*	20,068.0	*50.0%*
Pref Equity	0.0	*0.0%*	0.0	*0.0%*	0.0	*0.0%*	0.0	*0.0%*	0.0	*0.0%*
Total Capital	**20,231.4**	***100.0%***	**48,778.2**	***100.0%***	**41,631.6**	***100.0%***	**41,979.6**	***100.0%***	**40,111.9**	***100.0%***

Debt Summary Data

For the Fiscal Period Ending	30/09/2020		31/12/2020		31/03/2021		30/06/2021		30/09/2021	
Currency	*USD*		*USD*		*USD*		*USD*		*USD*	
	Millions	*% of Total*	*Millions*	*% of Total*	*Millions*	*% of Total*	*Millions*	*% of Total*	*Millions*	*% of Total*
Total Commercial Paper	1,650.0	*13.1%*	1,650.0	*6.3%*	1,650.0	*6.7%*	1,650.0	*6.7%*	1,650.0	*7.0%*
Total Revolving Credit	2,000.0	*15.9%*	4,000.0	*15.3%*	4,000.0	*16.2%*	4,000.0	*16.2%*	2,000.0	*8.4%*
Total Capital Leases	--	--	0.0	*0.0%*	--	--	--	--	--	--
General/Other Borrowings	8,915.0	*71.0%*	20,511.0	*78.4%*	19,098.4	*77.2%*	19,050.0	*77.1%*	20,074.8	*84.6%*
Total Principal Due	**12,565.0**	***100.0%***	**26,161.0**	***100.0%***	**24,748.4**	***100.0%***	**24,700.0**	***100.0%***	**23,724.8**	***100.0%***
Total Debt Outstanding	**12,565.0**		**26,161.0**		**24,748.4**		**24,700.0**		**23,724.8**	
Additional Totals										
Total Cash & ST Investments	703.6	*5.6%*	883.5	*3.4%*	844.8	*3.4%*	712.4	*2.9%*	795.3	*3.4%*
Net Debt	11,861.4	*94.4%*	25,277.5	*96.6%*	23,903.6	*96.6%*	23,987.6	*97.1%*	22,929.5	*96.6%*
Total Short-Term Borrowings	3,306.6	*26.3%*	3,502.3	*13.4%*	2,429.0	*9.8%*	3,574.4	*14.5%*	3,656.8	*15.4%*
Curr. Port. of LT Debt/Cap. Leases	3,306.3	*26.3%*	2,401.4	*9.2%*	2,392.1	*9.7%*	2,273.9	*9.2%*	1,997.0	*8.4%*
Long-Term Debt (Incl. Cap. Leases)	9,258.4	*73.7%*	22,658.7	*86.6%*	22,319.4	*90.2%*	21,125.6	*85.5%*	20,068.0	*84.6%*
Total Secured Debt	--	--	--	--	--	--	--	--	--	--
Fixed Rate Debt	--	--	--	--	--	--	--	--	--	--
Variable Rate Debt	--	--	--	--	--	--	--	--	--	--
Credit Ratios										
Net Debt/EBITDA	4.3x		12.6x		9.3x		7.3x		5.9x	
Total Debt/EBITDA	4.5x		13.0x		9.7x		7.5x		6.1x	
Operating Income/Total Debt	0.0x		0.0x		0.0x		0.0x		0.0x	
LTM FCF/Total Debt	0.1x		0.0x		0.1x		0.1x		0.1x	
LTM CFO/Total Debt	0.1x		0.0x		0.1x		0.1x		0.1x	
EBIT/Interest Expense	3.0x		-6.1x		-1.6x		-0.3x		2.4x	
EBIT/Total Interest Expense	3.0x		-6.1x		-1.6x		-0.3x		2.4x	
Degree of Financial Leverage	1.5x		--		--		--		1.7x	
(EBITDA-CAPEX)/Interest Expense	6.4x		-0.3x		6.5x		7.1x		8.3x	
EBITDA/Total Interest Expense	6.7x		0.5x		6.8x		7.6x		9.1x	
Debt Schedule										
Debt Schedule In Yr 1	--	--	2,250.0	--	--	--	--	--	--	--
Debt Schedule In Yr 2	--	--	--	--	--	--	--	--	--	--
Debt Schedule In Yr 3	--	--	--	--	--	--	--	--	--	--
Debt Schedule In Yr 4	--	--	--	--	--	--	--	--	--	--
Debt Schedule In Yr 5	--	--	--	--	--	--	--	--	--	--
Debt Schedule - Years 2 - 3	--	--	3,766.0	--	--	--	--	--	--	--
Debt Schedule - Years 4 - 5	--	--	3,499.0	--	--	--	--	--	--	--
Debt Schedule - Years 2 - 5	--	--	7,265.0	--	--	--	--	--	--	--
Debt Schedule Beyond Yr 5	--	--	14,432.0	--	--	--	--	--	--	--
Debt Schedule - Total Debt	**11,784.8**	***100.0%***	**--**	**--**	**24,357.5**	***100.0%***	**23,101.4**	***100.0%***	**21,762.4**	***100.0%***
Capital Lease Schedule										
Capital Leases - Year 1	--	--	--	--	--	--	--	--	--	--
Capital Leases - Year 2	--	--	--	--	--	--	--	--	--	--
Capital Leases - Year 3	--	--	--	--	--	--	--	--	--	--
Capital Leases - Year 4	--	--	--	--	--	--	--	--	--	--
Capital Leases - Year 5	--	--	--	--	--	--	--	--	--	--
Capital Leases - Years 2 - 3	--	--	--	--	--	--	--	--	--	--
Capital Leases - Years 4 - 5	--	--	--	--	--	--	--	--	--	--
Capital Leases - Years 2 - 5	--	--	--	--	--	--	--	--	--	--
Capital Leases Beyond Year 5	--	--	--	--	--	--	--	--	--	--
Total Future Value of Capital Leases	**--**	**--**	**0.0**	**--**	**--**	**--**	**--**	**--**	**--**	**--**
Present Value of ST Capital Leases	--		0.0		--		--		--	
Present Value of LT Capital Leases	--		0.0		--		--		--	
Operating Leases (Rental Expense) Schedule										
Rental Expense - Year 1	--	--	89.9	*24.8%*	--	--	--	--	--	--
Rental Expense - Year 2	--	--	68.0	*18.8%*	--	--	--	--	--	--
Rental Expense - Year 3	--	--	46.6	*12.9%*	--	--	--	--	--	--
Rental Expense - Year 4	--	--	34.6	*9.6%*	--	--	--	--	--	--
Rental Expense - Year 5	--	--	27.7	*7.7%*	--	--	--	--	--	--
Rental Expense - Years 2 - 3	--	--	114.6	*31.7%*	--	--	--	--	--	--
Rental Expense - Years 4 - 5	--	--	62.3	*17.2%*	--	--	--	--	--	--
Rental Expense - Years 2 - 5	--	--	176.9	*48.9%*	--	--	--	--	--	--
Rental Expense Beyond Year 5	--	--	95.1	*26.3%*	--	--	--	--	--	--
Total Sublease Income	--	--	--	--	--	--	--	--	--	--
Future Min Oper Lease Obligations	**--**	**--**	**361.9**	***100.0%***	**--**	**--**	**--**	**--**	**--**	**--**
Contractual Obligation Schedule										
Contractual Obligations - Year 1	--	--	4,061.7	13.0%	--	--	--	--	--	--
Contractual Obligations- Years 2-3	--	--	4,938.9	15.8%	--	--	--	--	--	--
Contractual Obligations- Years 4-5	--	--	4,446.9	14.2%	--	--	--	--	--	--
Contractual Obligations - Years 2 - 5	--	--	9,385.8	30.0%	--	--	--	--	--	--
Contractual Obligations - Beyond Year 5	--	--	17,798.2	57.0%	--	--	--	--	--	--
Total Contractual Obligations	**--**	**--**	**31,245.7**	**100.0%**	**--**	**--**	**--**	**--**	**--**	**--**
Purchase Obligations	**--**		**--**		**--**		**--**		**--**	
Interest Rate Data										
W/Ave. Interest Rate - Long-term Debt	--		--		--		--		--	

Bloomberg

Company In Depth Fundamentals - Segments

Ticker:	vtrs US EQUITY	vtrs US EQUITY	Ascend	Currency	Reporting / Change / USD
Period Type	Annuals	Consolidated	Yes	Accounting	Mixed

Viatris Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

REVENUE

Revenue by Product For the Fiscal Period Ending	31/12/2010	31/12/2011	31/12/2012	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020
Revenue	**5,450.52**	**6,129.83**	**6,796.10**	**6,909.10**	**7,719.60**	**9,429.30**	**11,076.90**	**11,907.70**	**11,433.90**	**11,500.50**	**11,946.00**
Generics	5,022.50	5,579.30	5,946.20	5,900.70	6,510.40	9,429.30	10,967.10	11,760.00	11,268.70	11,370.30	5,289.50
Brands	428.00	584.85	849.90	1,008.50	51.10	-	109.80	-	165.20	130.20	5,234.90
Complex Generics & Biosimilars	-	-	-	-	-	-	-	-	-	-	1,295.50
#N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-
#N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-
#N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-
#N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-
#N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-
#N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-
#N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-

Revenue by Geography For the Fiscal Period Ending	31/12/2010	31/12/2011	31/12/2012	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020
Revenue	**5,450.52**	**6,129.83**	**6,796.10**	**6,909.10**	**7,719.60**	**9,429.30**	**11,076.90**	**11,907.70**	**11,433.90**	**11,500.50**	**11,946.00**
Developed Markets	2,845.19	3,449.88	4,060.70	3,988.30	4,548.40	5,100.40	5,629.50	4,969.60	4,157.30	4,164.10	8,510.90
Emerging Markets	1,790.90	1,781.18	1,391.90	1,438.60	1,621.30	2,205.60	2,953.80	3,958.30	4,095.60	4,037.10	1,853.80
JANZ	768.17	875.21	1,297.60	1,429.70	1,476.80	2,056.60	2,383.80	2,832.10	3,015.80	3,169.10	1,195.30
Greater China	46.26	23.55	45.90	52.50	73.10	66.70	109.80	147.70	165.20	130.20	259.90
#N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-
#N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-
#N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-
#N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-
#N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-
#N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-

GROSS PROFIT BEF TAX

OPERATING PROFIT BEF TAX

Bloomberg

Company In Depth Fundamentals - Pension

Ticker:	vtrs US EQUITY	Sort	Ascend	Currency	Reporting	Change	USD
Period Type	Annuals	Consolidated	Yes	Accounting	Mixed		

Viatris Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Pension

For the Fiscal Period Ending	31/12/2010	31/12/2011	31/12/2012	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020
Currency	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*
Pension Net Periodic Cost											
Service Cost	--	--	--	--	5.00	11.90	17.40	20.10	19.20	20.70	23.50
Interest Cost	--	--	--	--	2.60	4.00	8.20	13.60	13.00	13.60	13.50
Expected Return on Plan Assets	--	--	--	--	(1.70)	(6.40)	(10.90)	(14.30)	(14.40)	(12.10)	(19.90)
Pension Expense (Income)	-	-	-	-	7.00	11.80	13.40	18.20	17.90	22.00	18.60
Other Postretirement Cost											
Service Cost	--	--	--	--	0.50	0.60	0.60	0.70	0.60	0.60	1.20
Interest Cost	--	--	--	--	1.00	1.10	1.30	1.60	1.50	1.50	1.40
Expected Return on Plan Assets	--	--	--	--	-	-	-	-	-	-	-
Other Postretirement Benefits Expense (I	-	-	-	-	-	-	-	-	2.30	5.50	2.90
Pension Funded Status											
Fair Value of Plan Assets	--	--	--	--	--	162.00	291.70	296.10	283.50	315.70	1,354.60
Actual Return (Loss) on Plan Assets	--	--	--	--	--	--	--	--	--	--	--
Employer Contribution	--	--	--	--	--	--	--	--	28.90	26.40	58.20
Benefits Paid	--	--	--	--	--	--	--	--	(24.90)	(23.90)	(24.60)
Projected Benefit Obligation	--	--	--	--	--	234.40	632.90	665.20	635.40	674.70	2,145.80
Over(Under) Funded Pension	--	--	--	--	--	(72.40)	(341.20)	(369.10)	(351.90)	(359.00)	(791.20)
Accumulated Benefit Obligation	--	--	--	--	--	--	--	--	--	--	--
Pension Funding Ratio	--	--	--	--	--	69.11	46.09	44.51	44.62	46.79	63.13
Other Postretirement Funded Status											
Fair Value of Plan Assets	--	--	--	--	--	-	-	-	-	-	-
Actual Return (Loss) on Plan Assets	--	--	--	--	--	--	--	--	--	--	--
Employer Contribution	--	--	--	--	--	--	--	--	2.50	9.40	1.70
Benefits Paid	--	--	--	--	(1.60)	(2.00)	(2.20)	(2.70)	(2.70)	(2.50)	(1.60)
Projected Benefit Obligation	--	--	--	--	--	--	--	--	34.00	33.80	188.80
Over(Under) Funded Post Ret Benefits	--	--	--	--	--	(26.00)	(38.00)	(35.10)	(34.00)	(33.80)	(188.80)
Other Post-Retirement Funding Ratio	--	--	--	--	--	--	--	--	-	-	-
Actuarial Assumptions											
Pension											
Expected Return on Plan Assets	--	--	--	--	--	--	--	--	4.90	4.30	4.30
Discount Rate used on Plan Liabilities	--	--	--	--	--	--	--	--	2.30	1.60	1.90
Rate of Compensation Increase	--	--	--	--	--	--	--	--	2.90	2.90	2.90
Other Postretirement Benefits											
Expected Return on Plan Assets	--	--	--	--	--	--	--	--	--	--	--
Discount Rate used on Plan Liabilities	--	--	--	--	--	--	--	--	4.30	3.30	3.30
Health Care Cost Trend Projected(next y	--	--	--	--	--	--	--	--	--	--	--
Pension Plan Asset Allocation											
Fair Value of Plan Assets	--	--	--	--	--	162.00	291.70	296.10	283.50	315.70	1,354.60
Asset Category - Equities %	--	--	--	--	--	--	--	--	43.92	28.29	45.28
Asset Category - Debt %	--	--	--	--	--	--	--	--	43.67	56.98	43.70
Asset Category - Real Estate %	--	--	--	--	--	--	--	--	--	--	--
Asset Category - Company Stock %	--	--	--	--	--	--	--	--	--	--	--
Asset Category - Cash %	--	--	--	--	--	--	--	--	1.38	1.24	3.82
Asset Category - Other %	--	--	--	--	--	--	--	--	11.04	13.49	7.19
Expected Pension Payments											
Year 1	--	--	--	--	--	--	--	--	32.00	33.20	104.50
Year 2	--	--	--	--	--	--	--	--	34.20	34.00	102.30
Year 3	--	--	--	--	--	--	--	--	35.70	34.70	104.90
Year 4	--	--	--	--	--	--	--	--	34.00	35.20	108.60
Year 5	--	--	--	--	--	--	--	--	36.40	38.90	106.90
Beyond Year 5	--	--	--	--	--	--	--	--	192.10	193.10	526.20
Expected Postretirement Benefits											
Year 1	--	--	--	--	--	--	--	--	1.70	2.00	16.40
Year 2	--	--	--	--	--	--	--	--	1.70	1.80	16.60
Year 3	--	--	--	--	--	--	--	--	2.00	1.90	16.50
Year 4	--	--	--	--	--	--	--	--	2.30	1.90	16.60
Year 5	--	--	--	--	--	--	--	--	2.20	2.00	16.30
Beyond Year 5	--	--	--	--	--	--	--	--	11.60	10.20	71.40

Bloomberg

Company In Depth Fundamentals - Supplemental

Ticker:	vtrs US EQUITY	Sort	Ascend	Currency	Reporting	Change	USD
Period Type	Annuals	Consolidated	Yes	Accounting	Mixed		

Viatris Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Supplemental

For the Fiscal Period Ending *Currency*	31/12/2010 *USD*	31/12/2011 *USD*	31/12/2012 *USD*	31/12/2013 *USD*	31/12/2014 *USD*	31/12/2015 *USD*	31/12/2016 *USD*	31/12/2017 *USD*	31/12/2018 *USD*	31/12/2019 *USD*	31/12/2020 *USD*
Options Activity											
Options Granted During Period	2.58	4.94	3.13	2.18	6.23	0.94	0.88	0.96	0.91	0.83	0.81
Options Outstanding End Of Period	23.84	23.60	16.62	13.56	16.21	7.73	7.70	7.20	6.82	6.35	6.71
Options Exercisable End of Period	16.45	15.58	9.37	8.01	7.65	5.15	5.67	5.54	5.13	4.77	5.28
Price											
Weighted Average Fair Value per Option	-	-	7.00	8.49	17.44	20.18	17.90	15.88	16.51	11.03	8.07
Avg Exercise Price (Options Outstanding)	-	17.42	19.54	22.05	33.21	31.85	33.38	35.17	36.61	36.97	35.36
Avg Exercise Price (Options Exercisable)	15.99	16.05	17.57	18.82	20.42	23.56	28.10	31.99	34.76	38.11	38.51
Stock Option Valuation Model	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Assumptions											
Stock Opt Valuation - Risk Free Rate (%)	-	-	1.00	1.10	1.90	1.70	1.40	2.20	2.80	2.50	1.00
Stock Opt Valuation - Expected Life (Yrs)	-	-	5.90	6.10	6.30	6.30	6.30	6.40	6.50	6.50	6.50
Stock Opt Valuation - Expected Volatil (%)	-	-	29.70	23.90	31.60	33.70	38.10	33.20	35.80	38.10	46.70
Stock Opt Valuation - Dividend Yield (%)	-	-	-	-	-	-	-	-	-	-	-
Stock Expense											
Expense For Stock-Based Compensation	31.40	42.58	42.60	47.00	66.00	92.80	88.90	74.70	(3.30)	56.80	79.20
Stock Option Expense (After Tax)	-	-	-	-	-	-	-	-	-	-	-